Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Nullscript

HDAC inhibitor
 
BML-GR327-0001 1 mg 70.00 USD
 
BML-GR327-0005 5 mg 278.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: ALX-270-302

Negative control compound for the histone deacetylase (HDAC) inhibitor scriptaid (Prod. No. BML-GR326).

Product Specification

Alternative Name:4-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-N-hydroxybutanamide
 
Formula:C16H14N2O4
 
MW:298.3
 
Source:Synthetic.
 
CAS:300816-11-9
 
Purity:≥97% (TLC)
 
Appearance:Yellow to off-white solid.
 
Solubility:Soluble in DMSO (4mg/ml) or ethanol (0.3mg/ml).
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C.
 
Handling:Protect from light.
 
bml-gr327
Please mouse over
bml-gr327

Product Literature References

Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition: M.R. Davis, et al.; BMC Cancer 16, 316 (2016), Application(s): Cell culture, Abstract; Full Text
A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library: G.H. Su, et al.; Cancer Res. 60, 3137 (2000), Abstract; Full Text

Related Products

Scriptaid 

HDAC inhibitor
287383-59-9, ≥97% (TLC) | Print as PDF
 
BML-GR326-0001 1 mg 68.00 USD
 
BML-GR326-0005 5 mg 270.00 USD
Do you need bulk/larger quantities?
 

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
HDAC
By biological activity:
HDAC Inhibitor
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Brochures
Stem Cells
Stem Cells
Download as PDF

Brochures
Epigenetics
Epigenetics
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,